NCT04687969View on ClinicalTrials.gov

Multimodal Machine Learning Characterization of Solid Tumors

Active, not recruitingOBSERVATIONAL
Enrollment

135

Participants

Timeline

Start Date

October 23, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2025

Conditions
Adenocarcinoma of ProstateRadical ProstatectomyHepatocellular Carcinoma (HCC)GliomaRenal Cell Carcinoma (RCC)Prostate Cancer
Interventions
DRUG

[18F]DCFPyL

will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination

RADIATION

PET/MRI scanner

PET/MRI Scan with \[18F\]DCFPyL as directed by protocol

Trial Locations (2)

02115

Massachusetts General Hospital, Boston

02215

Beth-Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ciprian Catana, MD, PhD

OTHER